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ABSTRACT
The primary function of the UBE2T ubiquitin con-
jugase is in the monoubiquitination of the FANCI-
FANCD2 heterodimer, a central step in the Fanconi
anemia (FA) pathway. Genetic inactivation of UBE2T
is responsible for the phenotypes of FANCT patients;
however, a FANCT patient carrying a maternal dupli-
cation and a paternal deletion in the UBE2T loci dis-
played normal peripheral blood counts and UBE2T
protein levels in B-lymphoblast cell lines. To test
whether reversion by recombination between UBE2T
AluYa5 elements could have occurred in the patient’s
hematopoietic stem cells despite the defects in ho-
mologous recombination (HR) in FA cells, we con-
structed HeLa cell lines containing the UBE2T AluYa5
elements and neighboring intervening sequences
flanked by fluorescent reporter genes. Introduction
of a DNA double strand break in the model UBE2T lo-
cus in vivo promoted single strand annealing (SSA)
between proximal Alu elements and deletion of the
intervening color marker gene, recapitulating the re-
version of the UBE2T duplication in the FA patient.
To test whether UBE2T null cells retain HR activity,
the UBE2T genes were knocked out in HeLa cells and
U2OS cells. CRISPR/Cas9-mediated genetic knock-
out of UBE2T only partially reduced HR, demonstrat-
ing that UBE2T-independent pathways can compen-
sate for the recombination defect in UBE2T/FANCT
null cells.
INTRODUCTION
Alu elements are the most abundant short interspersed ele-
ments (SINEs) in the human genome, numbering over one
million copies. These repetitive sequences are hotspots for
genetic intrachromosomal or interchromosomal recombi-
nation (1). The proximity of abundant Alu elements in the
genome clearly favors deletions by RAD51-independent in-
trachromosomal single strand annealing (SSA) (2). Alu-
mediated recombination (AMR) events contribute to mul-
tiple forms of cancer and other genetic disorders (3–8), and
are estimated to be responsible for 0.3% of human genetic
diseases (4,9). These repeated elements also drive genomic
evolution; it has been estimated that more than five hun-
dred Alu-mediated deletion events have occurred since di-
vergence of the human and chimpanzee genomes (9). Here,
we modeled an unusual somatic reversion event in a Fan-
coni anemia (FA) patient who had inherited a partial ge-
nomic duplication in the FANCT/UBE2T gene from his
mother. In the current model system, an in vivo double
strand break leads to homology-dependent recombination
between two UBE2T Alu elements, mimicking a contrac-
tion of the maternal duplication to restore the WT allele.
FA is a rare recessive or dominant DNA repair dis-
order characterized by genome instability, developmen-
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tal abnormalities, bone marrow failure and cancer pre-
disposition (10–12). Loss-of-function mutations in one X-
chromosomal (FANCB) and at least twenty autosomal re-
cessive genes (FANCA to RFWD3/FANCW) as well as
missense mutations in one dominant negative FA gene
(RAD51A/FANCR) result in the typical defects associated
with FA (13–15). At the cellular level in FA deficient cells,
genome instability in combination with erroneous repair
of DNA interstrand crosslinks (ICLs) and DNA double
strand breaks often results in complex genome rearrange-
ments (CGR), translocations and gene amplification (16–
18). Among the known activities of FA proteins are repli-
some stabilization during replication stress (17,19), the re-
moval of DNA ICLs caused by endogenous aldehydes (20),
the resolution of R-loops (21), stimulation of the alternative
end joining (Alt-EJ)/microhomology-mediated end joining
(MMEJ) of DNA double strand breaks (22), regulation of
the spindle assembly checkpoint (23,24), and autophagic
clearance of damaged mitochondria or viruses (25).
The diagnosis of FA is based on the combination of typ-
ical clinical symptoms and the characteristic hypersensi-
tivity of cells from affected patients to the ICL reagents
diepoxybutane (DEB), mitomycin C (MMC), melphalan or
cisplatin, which often are used to dissect the functions of in-
dividual FA proteins (18,26). A key step in activating ICL
repair is the monoubiquitination of FANCI and FANCD2
in the FANCI-FANCD2 (ID2) protein complex by the thir-
teen subunit FA core complex containing FANCL as the E3
ubiquitin ligase (reviewed in (26,27)). The FANCT/UBE2T
gene product is not part of this protein complex but en-
codes the major E2 ubiquitin conjugating enzyme used by
the FANCL E3 ligase to modify and activate the DNA-
bound ID2 dimer (28–31). Monoubiquitination of FANCI
and FANCD2 is necessary for their co-localization into nu-
clear foci. Additional roles for FANCI and FANCD2 in the
stabilization of replication forks and HR have also been re-
ported (17,30,32–35).
Machida et al. (36) and Alpi et al. (37) have shown that
UBE2T is the E2 conjugating ligase in the FA pathway and
that genetic deficiency inUBE2T−/− DT40 cells leads to the
classical cellular phenotypes of FA, including hypersensitiv-
ity to low doses of DNA ICL agents and high frequencies
of chromosomal abnormalities. Subsequently, three groups
including ours independently described three FA patients
with germ-line defects in the UBE2T gene, now also des-
ignated FANCT (18,38–40). The 16-year-old FA patient
(100166/1) of Italian ancestry described by us (40) was born
with bilateral malformations of both thumbs and radii, mi-
crocephaly, cafe´-au-lait spots and left kidney abnormality.
He was confirmed as being affected by FA due to high levels
of DEB-induced chromosomal breakage in metaphases of
peripheral blood lymphocytes at birth (40). We identified
the patient’s primary fibroblast cells as being defective in
UBE2T by overexpression of the wildtypeUBE2T cDNAas
a candidate FA gene (RefSeq: NM 014176.3) which entirely
corrected G2/M phase arrest and also other cellular phe-
notypes induced byMMC. Importantly, no mutation in the
UBE2T locus could be detected in the patient’s germ-line
DNA by Sanger sequencing or next-generation sequencing
of UBE2T, as he had inherited genomic rearrangements at
the two identical 311-bp AluYa5 elements present in the
same orientation in introns 1 and 6 of the human UBE2T
gene.
Notably, three Alu-mediated recombination events were
evident at the UBE2T locus In the FANCT−/− 100166/1
proband (40). From his heterozygous father, the patient had
inherited a large genomic deletion of exons 2–6, resulting
in an allele without any protein-coding transcript. From
his healthy mother, the patient inherited a UBE2T allele in
which a duplication of exons 2–6 had occurred, resulting
in a UBE2T locus with three identical AluYa5 repeats. Im-
portantly, this maternal allele was capable of expressing a
transcript for a truncated UBE2T protein that contained
the complete ubiquitin binding (UB) domain of UBE2T
(40). When overexpressed, this shorter protein completely
restored the defects in the FA pathway in UBE2T−/− cells
(40). However, western blot analysis revealed that no mu-
tant UBE2T protein was expressed from the duplicated ma-
ternal allele in either the patient’s or his mother’s cells, as
the mRNA from this allele was subject to nonsense medi-
ated RNA decay (40). The third recombination event in the
UBE2T locus occurred somatically in utero in a hematopoi-
etic stem cell, as the patient’s peripheral blood lympho-
cytes were already a mixture of normal and FA-deficient
cells when analyzed by chromosomal breakage three days
after birth (40). Here, it is safe to hypothesize that the
normal UBE2T allele was generated by intrachromosomal
SSA or unequal sister chromatid homologous recombina-
tion between the maternally duplicated Alu elements (Fig-
ure 1A), as no normal allele that could serve as a recombi-
nation donor is present in the patient’s cells. Sequencing of
FANCT−/− 100166/1 proband genomic DNA PCR prod-
ucts corroborated that the reversion had occurred at the
AluYa5 repeats within theUBE2T locus (40). Subsequently,
this ‘corrected’ hematopoietic stem cell repopulated the en-
tire hematopoietic system with normal progeny - a phe-
nomenon known as somatic mosaicism in FA (41)––and the
patient had normal peripheral blood counts for more than
15 years and never experienced bone marrow failure.
The two main branches of homology directed recombi-
nation (HDR) are RAD51-independent single strand an-
nealing (SSA) (42) and RAD51-dependent homologous re-
combination (HR) (43). To develop amodel to emulateAlu-
mediated homology directed recombination events in the
UBE2T locus and also for other loci in the genome, we
generated dual fluorescent reporter constructs using two in-
dependent expression cassettes for green (eGFP) and red
(dTomato) fluorescent proteins with three identical AluYa5
repeats in the same orientation. An exogenous I-Sce1 site
was included at either of two distinct locations in the re-
porter constructs to allow introduction of a single site-
specific DNA double strand break (DSB). After stable in-
tegration of one copy of the dual fluorescent reporter con-
struct into the genome of HeLa cells, we show that expres-
sion of the I-Sce1 protein in the cells promotes DNA break-
age and homology-directed AMR that mimics the reversion
which had happened in the patient’s hematopoietic cells.
Using the dual fluorescence system, we find that UBE2T
has a limited role in HR, and demonstrate the role of HDR
in Alu-mediated recombination in UBE2T using inhibitors
or knockdown of HDR or nonhomologous end joining
(NHEJ)-related proteins. Our results show that the dual flu-
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Figure 1. Modeling of the expandedUBE2T locus in dual fluorescence (DF) cells. (A)Wild type UBE2T gene, andmaternal and paternal genotypes. Exons
are numbered 1–7; yellow boxes, AluYa5 sequences; unfilled boxes, noncoding exons; filled boxes, coding exons. (B) DF1 cells contain a single genomic
integrant at the FLP recombinase target (FRT) site in HeLa/406 cells, containing three identical AluYa5 repeats (yellow) and portions of intervening
sequences IVS 1 and IVS 6 flanking the Alu repeats (blue boxes). The first and second Alu repeats are separated by a dTomato fluorescent protein gene
(red) driven by the hPGK promoter; the second and third Alu repeats are separated by an eGFP gene (green) driven by the SFFV U3 promoter. In the
DF2 cell line, an I-Sce1 cleavage site separates the dTomato and eGFP marker genes. In the DF3 cell line, an I-Sce1 cleavage site is located upstream of
the dTomato marker gene. Thin lines, vector sequences. hygR (hygromycin resistance), neoR (G418 resistance) and TK (HSV thymidine kinase, ganciclovir
sensitivity) are selection markers for integrant construction (Methods).
orescent HeLa cells are also a robust tool for the systematic
study of Alu-mediated recombination events and their role
in inducing human disease. Combined with knockdowns of
specific genes of interest, the dual fluorescence system can
quantitatively report on the contribution of specific proteins
to HDR and NHEJ.
MATERIALS AND METHODS
Dual Fluorescence (DF) plasmid constructs
The plasmids used in this work were constructed to avoid
regions of homology with the resident vector at the ectopic
integration site (44) or within the dual fluorescence vectors
other than the Alu/IVS elements. Standard cloning meth-
ods were used to construct the vector integrated in DF3
cells from the following components:LacZ (nt 1–120, 6917–
7374); AluYa5 (nt 135 – 445);UBE2T intron 1 (nt 446–626);
I-SceI recognition (nt 632–662); hPGK promoter (nt 663–
1204); dTomato (red fluorescent protein, nt 1222–1927);
bGHpA (nt 1936–2152); AluYa5 (nt 2167–2478);UBE2T in-
tron 6 (nt 2478–2658); SFFV U3 promoter (nt 2696–3036);
eGFP (enhanced green fluorescent protein, nt 3072–3792);
U3 (HIV 3′ LTRpartial sequence, nt 3885–3939); R (HIV-
1 partial sequence, nt 3940–4034); U5 (HIV-1 partial se-
quence, nt 4035–4120; AluYa5 (nt 4156–4467); UBE2T in-
tron 6 (nt 4467–4647; FRT site (nt 4724–4772); neomycin
phosphotransferase gene (nt 4781–5576); SV40 polyadeny-
lation sequences (nt 5577–6917); chloramphenicol acetyl-
transferase gene (nt 7822–8482); pSC101 origin of replica-
tion and RepA binding site (nt 10298–9406). Plasmids used
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to construct other cell lines were derived from the same
components. Further details are available from the authors.
As shown in Supplementary Figure S1 and confirmed by
the present results, there is insufficient homology between
the red and green fluorescent protein genes to enable ho-
mologous recombination.
Cell culture
DF cell lines were constructed by FLP recombinase me-
diated integration into HeLa/406 cells and drug selection
as described previously (45–50). All DF cell lines were
cultured in Dulbecco’s modified Eagle medium (DMEM,
Gibco) supplemented with 10% newborn calf serum (NCS)
at 37◦C, 5% CO2. The human osteosarcoma (U2OS, ATCC
HTB-96) DR-GFP cell lines were grown in DMEM sup-
plemented with 10% fetal bovine serum (FBS) at 37◦C, 5%
CO2.
Expression of I-Sce1 endonuclease
Stable DF cell lines plated at 6 × 105 cells were trypsinized
and transfected with 8 ug I-Sce1 plasmid and 10 l of Lipo-
fectamine 2000 (Invitrogen) per manufacturer’s protocol in
a six-well plate (Falcon). Medium was replaced after 24 h
to remove transfection complexes. The I-Sce1 plasmid pro-
duces an HA-tagged form of the I-Sce1 endonuclease. Peak
expression of I-Sce1 endonuclease was at 24 h and was un-
detectable after 72 h by western blot (Supplementary Fig-
ure S2). Cells were grown for 8 days after I-Sce1 transfec-
tion and split accordingly until harvested for flow cytome-
try. The I-Sce1 plasmidwas a gift from JohnTurchi (Indiana
University School of Medicine).
siRNA treatment
DF2 cell lines were plated at 4 × 105 cells/well in a six-
well tissue culture plate (Falcon). The cells were trypsinized
and transfected with 100 nM siCtIP siRNA (Hs RBBP8
SI1027416, Qiagen) and 10 l of Lipofectamine 2000 (In-
vitrogen) per manufacturer’s protocol. The siRNA is a pool
of an equimolar mixture of four different siRNAs targeting
the same transcript. Control experiments were performed
in parallel using a non-targeting AllStars siRNA (Qiagen
SI03650318). At 24 h, cells were trypsinized and transfected
with 8 ug I-Sce1 plasmid and 10 l of Lipofectamine 2000
to allow for 48 h siRNA treatment by the time I-Sce1 had
reached peak expression at 24 h.
Small molecule inhibitor treatments
Small molecule inhibitors were used at the following final
concentrations: RAD51i (B02, Sigma SML0364, 10 uM;
RI-1, Sigma SML1274, 40 uM; RI-2, Sigma SML1851, 20
M, 30 M), DNA-PKcs (NU7026, Selleckchem S2893,
10 M), caffeine (Sigma C0750, 2 mM), ATMi (KU60019,
Sigma SML1416, 1 M). The inhibitors were added to the
cell culture medium at the time of I-Sce1 plasmid transfec-
tion. 6× 105 cells were trypsinized and transfectedwith 8 ug
I-Sce1 plasmid, inhibitor and 10 l of Lipofectamine 2000
(Invitrogen) per manufacturer’s protocol in a six-well plate.
Each inhibitor was used for 3 days after transfection for ef-
ficient inhibition throughout the time of I-Sce1 expression.
Cell sorting (FACS)
DF2 cell lines were subjected to I-Sce1 transfection and al-
lowed 8 days of recovery before flow cytometry to allow
turnover of preexisting fluorescent proteins. The heteroge-
neous population (∼5 × 106 cells) was then prepared for
cell sorting by centrifugation at 300 × g for 3 min, 4◦C.
The pellet was resuspended in 1 ml FACS buffer (Hank’s
Balanced Salt Solution, 25 mM HEPES, 1 mM EDTA,
1% BSA and 2% FBS) and filtered through a 35 m cell
strainer tube (Falcon). Cell sorting was performed at the
Cincinnati Children’s Hospital Medical Center (CCHMC)
Research Flow Cytometry Core (RFCC) on a BD FACS
Aria II flow cytometer with two 96 well tissue culture plates
(single cell per well) (Corning) for each of the four flow cy-
tometry quadrants. Single cell clones from each well were
transferred to 10 cm tissue culture dishes (Corning). Once
the 10 cm dishes were ∼80% confluent the cells were har-
vested forDNAanalysis.DNAwas isolated using anEZNA
tissue isolation kit (Omega Bio-Tek) to serve as template in
PCR amplifications.
Polymerase chain reaction
PCR was performed using Lac-Forward (5′-CTTCAA
ATCCGACCCGTAGA-3′) and TK-Reverse (5′-GTAA
GTCATCGGCTCGGGTA-3′) primers. PrimeSTARGXL
polymerase (Takara) was used per manufacturer’s instruc-
tions for 50 l reactions using 120 ng template. Internal
control primers (Figure 3) were: forward 5′-CCCAACCT
ACACTAACCTTAACC and reverse 5′-CCACACCAAC
CTCCTCATAAT. Cycling conditions were as follows: de-
naturation, 98◦C, 10 s; annealing, 57◦C, 15 s; extension,
68◦C, 1 min for 30 cycles. PCR products were purified with
an EZNA Cycle Pure kit (Omega Bio-Tek) and 20 l of
each purified product was electrophoresed on a 1% ultra-
pure agarose gel (Invitrogen) to verify the sizes of the re-
combination products.
Flow cytometry
Flow cytometry was performed on the BD Accuri C6 flow
cytometer. 5 × 105 adherent cells were trypsinized (Gibco)
and centrifuged at 300 × g for 3 min. Supernatant was re-
moved and the cell pellet was resuspended in 300 l PBS.
The cells were centrifuged for another 3 min at 300 × g.
The supernatant was aspirated and the cell pellet was re-
suspended in 200 l PBS. The number of events counted
was set to 20 000 on medium flow. Color compensation
was set at correcting FL2 by subtracting 6.3% of FL1.
The color compensation and quadrant determination was
determined empirically to minimize spectral overlap using
marker DF6 and DF7 cell lines that produce only red fluo-
rescent dTomato protein or green fluorescent eGFP protein
respectively.
CRISPR-Cas9 knockdown
CRISPR guides that target UBE2T were selected us-
ing the design website http://crispr.mit.edu (51). Guide 2
(TTTGATACCTACGAGCTCGCAGG) was chosen after
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single cell cloning of transduced cells and western anal-
ysis. This guide RNA is complementary to intron 1, ap-
proximately 1.3 kb downstream of the UBE2T 5′ Alu ele-
ment. Briefly, LentiCRISPR v2 containing the puromycin
resistance-mediating pac gene was a kind gift from Feng
Zhang (Addgene plasmid #52961). Cloning of the guide
RNA into the LENTICRISPR v2 vector was performed
as specified by the Zhang laboratory protocol (52). Infec-
tious replication-deficient lentiviral particles in the VSV-
G pseudotype were generated as previously described (40).
DF3 and U2OS DR-GFP cell lines were transduced with
a lentivirus construct expressing Cas9 and the UBE2T
CRISPR sgRNA at an MOI of <1 and single-cell clones
were selected by puromycin treatment. Single cell clones
were tested by western blot for loss of UBE2T expression
(40). Control cell lines underwent the same procedures but
were transduced with the empty LentiCRISPR v2 vector
that does not produce the UBE2T CRISPR guide.
Retroviral UBE2T expression vectors
In order to demonstrate that UBE2T deficiency of
UBE2T−/− HeLa cells generated through CRISPR/Cas9
was indeed responsible for the DNA repair defects, a retro-
viral vector was constructed that overexpressed the wild-
type UBE2T cDNA. As the UBE2T−/− HeLa cells were
already resistant to neomycin, puromycin and hygromycin,
the cDNAof the blasticidin resistence gene was cloned from
the pHAGE.CMV.EG SLX4 vector (a kind gift of Agata
Smogorzewska, Rockfeller University, NY, USA) and in-
serted into the retroviral pS91 UBE2T-IRES-puroR vector
using NcoI-ClaI. The final retroviral vector expressed the
blasticidin resistence gene after the IRES site. Infectious re-
combinant retroviral particles with the VSV-V phenotype
were produced in 293T cells and used to transduce theHeLa
cells at a multiplicity of infection of <0.2, as described pre-
viously (40).
RESULTS
Construction of dual fluorescence (DF) reporter constructs
for the maternal UBE2T locus
The wild-typeUBE2T allele in humans comprises seven ex-
ons with the translation start in exon 2, and two identical
AluYa5 elements in the same orientation (www.ensembl.
org). The first Alu element is located ∼180 bp 3′ of the
exon1/intron 1 border, and a second Alu element is ∼180
bp 3′ of the exon 6/intron 6 border (Figure 1A). The mu-
tant maternal allele contains a duplication of exons 2–6 and
the mutant paternal allele exhibits a deletion of exons 2–6.
Both mutant alleles seem to have occurred by Alu-mediated
recombination. We have shown previously that the paternal
allele is present as a founder mutation at low frequencies in
the Italian and the German populations. However, we did
not detect thematernal duplication in almost 2000 individu-
als (40) suggesting that it is much more restricted to the ma-
ternal lineage. In the proband, spontaneous deletion of the
maternally duplicated exons 2–6 by recombination between
neighboring Alu elements has been postulated to account
for the outgrowth of normal blood cells and the reversion
of the hematopoietic phenotypes (40).
To simulate Alu-mediated recombination in the UBE2T
locus, we generated clonal cell lines in which one copy of a
model UBE2T locus was integrated into the single FLP re-
combinase target (FRT) site in HeLa/406 cells (45–49,53)
(Figure 1B). Previous work has shown that Alu-mediated
recombination is responsible for homozygous deletions in
the STK11/LKB1 locus of HeLa cells to generate aberrant
LKB1 fusion transcripts (54), for MLL/KMT2A duplica-
tions in normal and AML hematopoietic cells (55), and
for nonallelic homologous recombination deletions in the
FANCA, B, C and D2 genes (5,56) in FA patient cells.
To model the maternal UBE2T allele containing the du-
plication, three AluYa5 repeats and ∼180 bp of UBE2T
flanking intron 1 (IVS1) or intron 6 (IVS6) sequences were
separated by complete reporter gene cassettes encoding the
red fluorescent protein (RFP) dTomato driven by the hu-
man phosphoglycerate kinase (PGK) promoter with a 3′
bGH polyA site, and the eGFP protein driven by a mod-
ified viral SFFVU3 promoter region followed by the polyA
sequences of a SIN lentiviral LTR (57).
There is no sequence overlap between the promotors and
polyA sites of the expression cassettes. In addition, the
dTomato and eGFP ORFs have minimal sequence overlap
and only two identical nucleotide stretches at the 5′ and 3′
ends of 21 and 25 bp (Supplementary Figure S1), respec-
tively. For clarity, we have numbered the AluYa5 elements
Alu 1, 2 and 3 in our reporter constructs (Figure 1B), al-
though these elements comprise the identical 311 bp se-
quence. Dual Fluorescence 1 (DF1) cells do not contain a
cleavage site for I-Sce1, while in Dual Fluorescence 2 (DF2)
cells a cut site for I-Sce1 preceded the eGFP gene (Figure
1B). In DF3 cells the I-Sce1 cut site was placed upstream of
the dTomato gene (Figure 1B).
Dual fluorescence cells to monitor the repair of DSBs in the
presence of Alu repeats
DF1, 2 and 3 cells initially expressed both red dTomato and
green eGFP markers, and appeared yellow under UV il-
lumination (Figure 2A). These cells were then transfected
with a plasmid that expressed the I-Sce1 endonuclease max-
imally at 24 h post transfection (Supplementary Figure S2)
to introduce a unique DSB within the DF2 and DF3 re-
porter constructs. As shown in Figure 2A, DF1 cells did
not change color (yellow) following transfection with the
I-Sce1 expression plasmid as the DF1 construct does not
harbor an I-Sce1 site. In contrast, a substantial fraction
of DF2 cells showed red fluorescence associated with the
loss of eGFP (RFP+, eGFP–) and only a smaller pro-
portion of cells turned green (RFP– eGFP+) after I-Sce1
transfection, while DF3 cells preferentially turned green
(RFP–, eGFP+). These data suggest that a single DNA
double strand break between identical Alu repeats can ef-
ficiently induce recombination events leading to loss of
the intervening color reporter gene, consistent with Alu-
mediated intrachromosomal SSA or unequal homology-
dependent recombination between sister chromatids.
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Figure 2. DSB-induced recombination in DF cells. (A) I-Sce1 expression does not cause loss of either color marker gene in DF1 cells, but leads to prefer-
ential loss of eGFP expression in DF2 cells, and preferential loss of dTomato expression in DF3 cells. (B) Key to flow cytometry profiles. In the absence of
I-Sce1 digestion cells contain dTomato (RFP+) and eGFP (GFP+) marker genes and appear in the upper right quadrant (DP, double positive). Loss of
the eGFP gene renders cells red (R, upper left, RFP+, GFP–). Loss of the dTomato gene renders cells green (G, lower right, GFP+, RFP–). Loss of both
marker genes renders cells double negative (DN, lower left, RFP–, GFP). (C–E) flow cytometry profiles of untreated (no I-Sce1) or I-Sce1 transfected (+
I-Sce1) (Methods) DF1, DF2, or DF3 cells, respectively. The data shown are representative of four or more experiments on each cell type. F, PCR analysis
of control and I-Sce1 treated DF cell lines. •, I-Sce1-dependent aberrant recombination product.
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Quantitation of homology directed recombination events by
flow cytometry
DF1, 2 and 3 cells were initially>95% double positive (DP)
(RFP+, eGFP+) (Figure 2B–E). It is predicted that ho-
mologous recombination between proximal Alu elements
would produce redDF2 cells by Alu 2/3 recombination and
green DF3 cells by Alu 1/2 recombination, while recom-
bination between distal Alu 1/3 elements would produce
double negative cells. We observed that in vivo I-Sce1 ex-
pression did not significantly change the flow profile of DF1
cells which lack an I-Sce1 site (Figure 2C). However, repre-
sentative results show that after I-Sce1 transfection, >30%
of DF2 cells lost the eGFP marker (red, RFP+, eGFP–;
upper left quadrant) (Figure 2D), and >30% of DF3 cells
lost the dTomatomarker (green, RFP–, eGFP+; lower right
quadrant) (Figure 2E). Approximately 10% of DF2 or DF3
cells lost both color markers (double negative (DN) RFP–,
eGFP–; lower left quadrant), most probably due to recom-
bination between the outermost Alu elements (Alu 1/3).
To confirm the extent of I-Sce1 induced deletions, we per-
formed PCR across the ectopic integration site in each of
the reporter cell lines. Lanes 1 and 2 (DF1 andDF1+I-Sce1)
showed no deletions in the reporter construct in the DF1
cells upon I-Sce1 expression (Figure 2F), as anticipated.
In contrast, I-Sce1 digested DF2 and DF3 cell DNAs dis-
played distinct lower molecular weight major bands (Figure
2F, lanes 4, 6) corresponding to deletion products expected
of recombination between the proximal (Alu 1/2) and distal
(Alu 2/3) Alu sites, consistent with the changed flow cytom-
etry patterns of these cells after I-Sce1 expression. Specif-
ically, recombination between the homologous Alu 1 and
Alu 2 sites was found to generate a major PCR band of ap-
proximately 3.5 kb after deletion of the dTomato gene in
RFP–, eGFP+ (green) DF2 cells (3.4% of total cells) and
DF3 cells (30.2% of total cells).
Recombination between Alu 2 and Alu 3 generated a
major PCR band of approximately 3.5 kb and deleted the
eGFP gene in RFP+, eGFP– (red) DF2 cells (33.8% of total
cells) andDF3 cells (1.1% of total cells). Recombination be-
tween Alu 1 and Alu 3 generated a major 1.4 kb PCR band
and deleted both the dTomato and eGFP genes in RFP–,
eGFP– (double negative) DF2 (9.7% of total cells) or DF3
cells (14.6% of total cells). Thus, in I-Sce1 treated DF2 or
DF3 cells, more than ∼45% of the cells underwent recom-
bination (red, green, double negative cells).
As described in detail below, we estimated the percentage
of DF2 double positive cells that had undergone recombi-
nation in vivo after I-Sce1 transfection, by in vitro I-Sce1
digestion of a full-length PCR product spanning the DF2
ectopic site. Since the DF2 full-length PCR product could
only have come from double positive cells, and more than
∼60% of this PCR product was resistant to in vitro I-Sce1
cleavage (Figure 4I), these results indicate that >75% of
the ectopic sites (45% recombinant cells plus 60% of dou-
ble positive cells (53.1% of total) had been cut by I-Sce1 in
vivo and then further processed by DNA repair. Thus, Alu-
mediated homology-directed recombination events had oc-
curred in >30% of DF2 cells (red) and DF3 cells (green)
following introduction of the I-Sce1 DSB within the re-
porter constructs. However, based on the resistance of the
ectopic site PCR product to in vitro I-Sce1 digestion, addi-
tional repair mechanisms (e.g. NHEJ/MMEJ) were also ac-
tive in >60% of cells where both fluorescent reporters were
retained.
Single colony PCR characterization of recombinants
Because standard PCR on DNA from unsorted cultures
may not disclose recombination products that arise from
minor percentages of the total cell population, we took a
single colony PCR approach to assess the fluctuation be-
tween cells following I-Sce1 digestion. Eight days after I-
Sce1 plasmid transfection, DF2 cells were FACS sorted into
individual double positive, red, green, and double negative
cells and clonally expanded. Genomic DNA was harvested
from randomly selected clones and amplified by PCR with
primers across the ectopic site. In DNA from double posi-
tive (RFP+, eGFP+) DF2 cells, PCR across the single ec-
topic site (Figure 3A) generated a major band of ca. 5.7 kb
in addition to bands of lesser intensity that presumably re-
sulted from recombination during clonal expansion (Figure
3B). The majority of red (RFP+, eGFP–) cells displayed a
major band of ca. 3.3 kb, consistent with recombination by
sister chromatidHRor intrachromosomal SSAbetween the
Alu 2 and Alu 3 elements flanking the I-Sce1 site (Figure
3C).
None of the colonies that turned green (RFP–, eGFP+)
showed the ca. 3.3 kb band predicted by homology-directed
repair between Alu 1 and Alu 2, but apparently had under-
gone a more complex series of recombinations generating
smaller and larger PCR products that retained the eGFP
gene and PCR primer binding sites (Figure 3D). Surpris-
ingly, only aminority of the double negative (RFP–, eGFP–
) cell clones showed the expected recombination between
Alu 1 and Alu 3 (Figure 3E, lane 9).
The differences in the PCR profiles of the DNA from
unsorted vs. sorted cells was striking. Following PCR of
DNA from unsorted cells (Figure 2F), the most abundant
cell population gave the expected ca. 3.5 kb PCR product,
although these may still have comprised a minor percent-
age of the total cells. In contrast, in the PCR of DNA from
sorted and cloned cells (Figure 3), even the lesser abundance
green cells could give products that were different from the
expected Alu 1/2 recombinant.
The data of Figures 2 and 3 argue that the most plau-
sible mechanism of in vivo reversion of the maternally du-
plicated UBE2T gene resulted from a spontaneous double
strand break that led to homology-directed recombination
between Alu 2 and Alu 3 elements. Additionally, it is likely
that a substantial percentage of breaks did not recombine
by classical RAD51-dependent homologous recombination
to restore the WT allele, but instead resulted in cells carry-
ing alternative recombinations that were selected against in
the patient’s hematopoietic compartment.
Role of DNA repair proteins in Alu-mediated recombination
at the model UBE2T locus
To test the mechanism of recombination in the model
UBE2T locus further, DF2 cells were exposed to I-Sce1
while proteins involved in nonhomologous end joining
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(NHEJ) or HR were chemically inhibited or knocked down
by siRNA. First, we treated I-Sce1 transfected DF2 cells
with caffeine (Figure 4A), which preferentially inhibits the
major DNA repair kinases ATM (ataxia telangiectasia mu-
tated) and ATR (ataxia telangiectasia and RAD3-related)
(58–60). Compared to control cells digested with I-Sce1
(Figure 4B), caffeine significantly decreased the percentage
of red, green, and double negative cells, and consequently
increased the fraction of double positive cells (Figure 4C,
H). This effect on recombination efficiency was more dra-
matic when using the ATM specific inhibitor KU60019
(Figure 4D, H), consistent with the stimulation of DSB end
resection and downstream steps in HR and NHEJ by ATM
(58–62).
The CtIP (C-terminal binding protein 1 interacting pro-
tein) nuclease catalyzes an early step in end resection
of DNA DSBs in conjunction with the MRN complex,
thereby terminating NHEJ and initiating HR (63–66).
siRNA-mediated inhibition of CtIP (Figure 4E, H) or
chemical inhibition of the RAD51 recombinase (RAD51i
B02, Figure 4F, H; RAD51i RI-1, RAD51i RI-2, Sup-
plementary Figure S3) also significantly decreased the
homology-directed recombination that produced red cells
upon I-Sce1 digestion. In contrast, specific inhibition of the
NHEJ protein DNA-PKcs by NU7026 (67) did not signifi-
cantly change the percentage of red cells (Figure 4G, H), as
expected if RFP+, eGFP– cells resulted from HR or SSA.
Inhibition of NHEJ by NU7026 decreased the percentage
of double negative and green cells, but increased the per-
centage of double positive (yellow) cells, most likely by pro-
moting precise religation of the I-Sce1 cut (68).
To distinguish between in vivo precise religation vs. muta-
genic NHEJ of the cleaved I-Sce1 site, we carried out PCR
across the ectopic site in DNA from DF2 cells transfected
with I-Sce1. We then digested the PCR product with I-Sce1
in vitro (Figure 4I). DF2 cells transfected with I-Sce1 and
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treated with caffeine or ATMi showed increased in vitro cut-
ting of the ectopic site PCR product relative to cells treated
with siControl (Figure 4I, lanes 1–3). Inasmuch as these
cells displayed reduced homology-directed repair (i.e. red
cells, Figure 4C, D, H), we conclude that the increased in
vitro cutting of the PCRproduct reflected an increase in pre-
cise ligation in vivo. In contrast, the ratio of in vitro cut to
uncut PCR product was reduced in DNA from cells treated
with siCtIP or RAD51i (Figure 4E, F, H). Finally, inhibi-
tion of NHEJ by DNA-PKcsi resulted in an increase in the
ratio of cut vs. uncut PCR product (Figure 4I, lane 6). Since
DNA-PKcsi did not significantly change HDR (Figure 4H),
we presume this increased cutting in vitro is due to enhanced
precise ligation whenDNA-PKcs andNHEJ end processing
are inhibited in vivo.
Based on the results of PCR in the FACS sorted cell
clones (Figure 3D, E), we hypothesize that NHEJ was in-
volved in the aberrant recombination occurring in the dou-
ble negative (RFP–, eGFP–) and green (RFP–, eGFP+) I-
Sce1 transfectedDF2 cells.While the results of CtIP knock-
down and RAD51i treatment are consistent with a reduc-
tion in HR, CtIP is also required for SSA (69), and knock-
down of CtIP end resection can also be compensated by in-
creased NHEJ (70,71), which would reduce in vitro I-Sce1
cutting. Although small-molecule RAD51 inhibitors have
been shown to reduce HR (72–75), the possibility of off-
target effects of these compounds remains.
Therefore, we sought an additional test of whether
RAD51-dependent HR was responsible for contraction of
the model UBE2T locus that produced red (RFP+, eGFP–
) DF2 cells. As shown in Figure 5, we assayed the effects
of knocking down BRCA2 (Figure 5A), which interacts
with RAD51 and controls its translocation into the nu-
cleus, nucleofilament formation and assembly of RAD51
foci in response to DNA damage (76–79). I-Sce1 was ex-
pressed in DF2 control cells or cells treated with BRCA2
siRNA (Figure 5B-F). The percentage of double positive
(RFP+, eGFP+) cells increased significantly with BRCA2
knockdown (Figure 5F). By contrast, BRCA2 knockdown
had no effect on the fraction of red cells produced by I-
Sce1 expression. Instead, the percentage of green (RFP–,
eGFP+) and double negative (RFP–, eGFP–) cells both de-
creased when BRCA2 was depleted. Conversely, the frac-
tion of double positive cells was increased by compensating
NHEJ/MMEJ, and mutagenic recombinations which pro-
duce green and double negative cells (Figure 3) were also
enhanced. Thus, the change in the percentages of double
positive, double negative and green cells indicates the bio-
logical effectiveness of the BRCA2 knockdown, while the
absence of an effect on the percentage of red cells argues that
BRCA2-independent SSA is responsible for the DF2 Alu-
mediated contraction, and that downregulation of HR by
BRCA2 depletion promotes alternative, mutagenic forms of
recombination (80–83).
Cis-acting effects of the Alu 1/IVS1 sequence on recombina-
tion at the model UBE2T locus
Digestion of DF2 cells with I-Sce1 resulted in the expected
1.4 kbAlu 1/3 recombination product whenDNA from un-
sorted cells was analyzed (Figure 2F), however, only about
9% of the cells fell in the double negative population (Figure
2D) and only 1 of 9 randomly selected double negative cell
clones produced the 1.4 kb PCR product predicted to arise
from Alu1/3 recombination (Figure 3D). To determine if
Alu 1/IVS1 was exerting an effect in cis on homology di-
rected recombination between Alu2/3, two additional cell
lines, DF4 and DF5, were constructed that deleted Alu
1/IVS1 (Figure 6A). The DF4 cell line differs from DF5
in that DF4 does not contain an I-Sce1 site; consequently,
I-Sce1 transfection did not change the flow cytometry pro-
file of DF4 cells (Figure 6B). I-Sce1 digestion of DF2 or
DF5 cells resulted in similar percentages of double positive
cells (Figure 6C, D). Surprisingly, I-Sce1 expression in DF5
cells (Figure 6C) produced approximately half as many red
(RFP+, eGFP–) cells and twice as many double negative
(RFP–, eGFP–) recombinants as in I-Sce1 digested DF2
cells (Figure 6D). This result indicates that Alu 1/IVS1 acts
in cis to promote Alu 2/3 homology-directed recombina-
tion to yield red cells, and to suppress recombination lead-
ing to double negative cells.
The decrease in the percentage of DF5 red cells after I-
Sce1 transfection is not due to reduced efficiency of I-Sce1
digestion, as the total percentage of red, green and double
negative cells was closely similar between I-Sce1 digested
DF2 and DF5 cells, but the ratio of green:red:double nega-
tive recombined cells changed from approximately 1:10:2.5
in DF2 cells to approximately 1:2:3 in DF5 cells. To ana-
lyze the I-Sce1 induced deletions, we performed PCR across
the ectopic site in DF4 and DF5 cells. The gel of Figure 6F
confirmed that I-Sce1 digested DF5 cells displayed a lower
molecular weight band of ∼3.1 kb corresponding to the
deletion product expected for recombination at the Alu 2
and Alu 3 sites, consistent with the flow cytometry patterns
of these cells (Figure 6C, D; RFP+, eGFP–).
We also observed that ∼22% of the I-Sce1 digested DF5
cells were double negative (RFP–, eGFP–). Taken with the
PCR results on double negative cell DNA in Figure 3C, we
judged that amplified PCR products smaller than 3.1 kb re-
tained the PCR primer binding sites and were the result of
excessive nuclease digestion at the I-Sce1 break or sponta-
neous breakage and recombination at sites other than the
Alu 2 and Alu 3 repeats.
Effect of UBE2T knockout on homology directed recombina-
tion
The conclusion that a recombination event with genera-
tion of a wild-type UBE2T allele in the FANCT patient
is the direct consequence of homology directed recombina-
tion (HDR) and the reason for the phenotypic reversion in
a hematopoietic cell containing the inherited partial dupli-
cation of the UBE2T gene, is based on the supposition that
FANCT/UBE2T deficient cells can still perform HDR. Be-
cause several FA proteins, including UBE2T, have been im-
plicated in multiple forms of DNA repair including homol-
ogy directed recombination (26,84,85), we wished to test di-
rectly the effect of UBE2T loss on HDR efficiency. Thus,
lentivirus-mediated CRISPR-Cas9 was used to knockout
the UBE2T genes in DF3 cells (UBE2TΔ cells) (Figure 7A)
and then single cell clones were expanded. Homology di-
rected repair of the I-Sce1 cut in DF3 cells (Figure 7B) is
Nucleic Acids Research, 2019, Vol. 47, No. 7 3513
1ecS-I +lortnoCis + 2FD1ecS-I on  ,lortnoCis + 2FD
2ACRBis + 1ecS-I + 2FD1ecS-I on ,2ACRBis + 2FD
% 1.89% 0.0
% 5.0% 4.1
% 6.34% 3.62
8.3 %21.8 %
59.5 %
4.6 %
25.6 %
10.3 %
% 8.69% 0.0
0.8 %2.4 %
F
0
4000
8000
12000
16000
ce
ll 
nu
m
be
r
DP
5300.0<psn2000.0<p p<0.004
ED
CB
siControl
siBRCA2
I-Sce1
+
+
+
-
+
-
+
+
+
-
+
-
-
-
-
+
-
R
+
+
-
+
-
-
-
+
+
-
G
+
+
-
+
-
-
-
-
+
-
+
DN
+
+
-
+
-
-
+
+
-
-
20000
A
BRCA2
β‐actin
kDa
385
40
Figure 5. BRCA2 knockdown does not affect Alu-mediated SSA, but enhances end joining and mutagenic recombination. (A) Western blot of whole cell
extracts of DF2 cells treated with siControl or siBRCA2. (B) Flow cytometry profile of DF2 cells treated with control siRNA. (C) Flow cytometry profile
of DF2 cells treated with control siRNA and I-Sce1. (D) Flow cytometry profile of DF2 cells treated with BRCA2 siRNA. (E) Flow cytometry profile of
DF2 cells treated with BRCA2 siRNA and I-Sce1. (F) Quantitation of flow cytometry results. Values are means + S.D. of three biological replicates each
assayed in triplicate (paired Student’s t-test). P values compare I-Sce1 treated samples ± BRCA2 siRNA.
3514 Nucleic Acids Research, 2019, Vol. 47, No. 7
1.5 %
0.0 %
2.5 %
96.0 %
A
C
DF5 cells
I-Sce1
TKHyg Neo Tomato eGFP
TRFTRF
Alu
2
IVS6 Alu
3
IVS6
D
5.2 kb
IVS6Alu
2
IVS6Alu
3
RFP + , eGFP +
•
3.1 kb
IVS6Alu
2/3
RFP + , eGFP -
E
2.0 % 2.5 %
0.1 % 95.4 %re
d
green
DF4 + I-Sce1
22.4 % 6.8 %
14.4 % 56.4 %
DF5 + I-Sce1
B
re
d
green
DF4 no I-Sce1
0.0 %1.1 %
0.0 % 98.8 %
DF2 no I-Sce1
4.6 %
0.1 % 92.7 %
DF5 no I-Sce1
2.6 %
F
DF2 + I-Sce1
8.4 % 
34.6 % 53.7 % 
3.3 % 
1    Kb
2    Kb
3    Kb
5    Kb
1.6 Kb
20000
12000
8000
4000
0
DF2 no I-Sce1
DP R G DN
DF2 + I-Sce1
p<0.0008
DF5 no I-Sce1 DF5 + I-Sce1
16000
DP R G DN
p<0.0005
p<0.0015
p<0.0005
p<0.0030
p<0.0062
p<0.0022
ns
p<0.0019
p<0.00061
p<0.0135
p<0.0058
DP R G DN DP R G DN
Figure 6. Cis-acting effects of the Alu 1/IVS1 sequence on recombination at the model UBE2T locus. (A) DF4 cells contain the same genomic integrant as
DF1 cells except for deletion of the first AluYa5 element and IVS1 fragment. DF5 cells contain the same integrant as DF4 cells, but also contain an I-Sce1
site upstream of the eGFP gene (as in DF2 cells). (B–D) flow cytometry profile of DF4, DF2 or DF5 cells, respectively, either untreated or transfected
with I-Sce1. (E) Quantitation of flow cytometry results. DP, double positive; R, red; G, green; DN, double negative. Data are the means + S.D. of three
biological replicates each assayed in triplicate (paired Student’s t-test). Values of P > 0.05 were considered not significant (ns). F, PCR analysis of control
and I-Sce1 treated DF4 and DF5 cell lines. •, I-Sce1-dependent aberrant recombination product.
Nucleic Acids Research, 2019, Vol. 47, No. 7 3515
CA
B
D
0.0% 96.0% 0.1% 60.6%
0.0% 97.5% 0.1% 78.0%
DF3 no I-Sce1
re
d
green
iGFPGFP
iGFP
I-Sce1 + I-Sce1
GFP
E
LC KO LC KO
U2OSDF3
55 -
25 -
15 -
kDa
- -actin
- UBE2T
1.4% 2.6% 15.2% 24.1%
10.1% 11.8%1.1% 1.3%
DF3 + I-Sce1
DF3 KO no I-Sce1 DF3 KO + I-Sce1
Alu
1
IVS1 IVS6Alu
2
IVS6Alu
3
I-Sce1
U2-OS UBE2T -/-
100%
80%
60%
40%
20%
0%
KO KO + 
EV
KO
+ UBE2T
LC LC +
EV
LC + UBE2T
R
el
at
iv
e 
%
 G
FP
 +
ce
lls
naïve 
control
F
p<0.020
p<0.019
0
4000
8000
12000
16000
WT KO UBE2T+
DN
ce
ll 
nu
m
be
r
WT KO UBE2T+
G
WT KO UBE2T+
R
WT KO UBE2T+
DP
p<0.005
p<0.003
ns p<0.005
p<0.003
p<0.05
p<0.05
DF3
Figure 7. UBE2T knockout partially inhibits HR. (A) CRISPR-Cas9 knockout of UBE2T in DF3 and U2OS cells (western blot). Note the greater abun-
dance of UBE2T in tetraploid DF3 cells. (B) Schematic of the DF3 cell line construct. (C) Representative flow cytometry profiles of DF3 control cells and
UBE2T CRISPR knockout DF3 cells with or without I-Sce1 digestion. (D) Quantitation of flow cytometry profiles of triplicate biological replicates as-
sayed in triplicate. Values are the means + S.D. (paired Student’s t-test). KO, CRISPR knockout DF3 cells;UBE2T+, KO cells reconstituted with lentiviral
UBE2T cDNA. (E) DR-GFP schematic. (F) Quantitation of homology directed repair in U2OS control cells and UBE2T−/− CRISPR knockout (KO)
U2OS cells. Naı¨ve, unedited U2OS cells; KO, CRISPR knockout of UBE2T; KO + EV, KO cells treated with lentivirus empty vector; KO + UBE2T, KO
cells reconstituted with lentiviralUBE2T cDNA; LC, cells treated with control lentiviral vector. Values are means + S.D. of three biological replicates each
assayed in triplicate (paired Student’s t-test).
3516 Nucleic Acids Research, 2019, Vol. 47, No. 7
predicted to yield green cells (RFP–, GFP+; Figure 7C). To
assess the efficiency of homologous recombination we com-
pared the levels of green cells produced when naı¨ve DF3
cells or UBE2TΔ DF3 cells were transiently transfected
with the I-Sce1 vector. Compared to naı¨ve cells, UBE2TΔ
cells showed an approximate 50% decrease in the percent-
age of RFP–, eGFP+ (green) cells (Figure 7C, D). We
conclude that significant homology-directed recombination
could still occur at the Alu repeats in the model UBE2T al-
lele ofUBE2TΔ cells when a DSB breaks occurred between
flanking Alu repeats.
For comparison, theUBE2T genes were also knocked out
in U2OS cells using CRISPR-Cas9 lentivirus (Figure 7A).
TheUBE2T−/− knock-outU2OS cells contain the direct re-
peat (DR-GFP) construct (Figure 7E), which has been used
widely as a reporter for HR (86–91). In these cells, the up-
stream SceGFP gene is inactive due to the presence of a
stop codon within the I-Sce1 cleavage site, while a second
partial GFP fragment of 812 bp (iGFP) is present 3.7 kb
downstream on the same chromosome. I-Sce1 cleavage of
this construct can lead to a homology-dependent gene con-
version event between the iGFP and the broken SceGFP se-
quence, and thereby restore a functional GFP protein which
can be measured by flow cytometry.
Biallelic CRISPR-Cas9 knockout of the U2OS cell
UBE2T genes (UBE2T−/−) resulted in a significant de-
crease in GFP + cells after I-Sce1 cleavage compared to
naı¨ve control U2OS cells or the same U2OS UBE2T−/−
cells corrected with a viralUBE2T cDNA expression vector
(KO + UBE2T; Figure 7F). These results showed that the
UBE2T protein contributes to the efficiency of homology
dependent repair, however, it is not absolutely required for
HR repair to occur. The observation that UBE2T−/− cells
retained more than half of the HR activity of UBE2T+/+
cells implies that redundant pathways to homology directed
repair are active in these engineered FA-T cells.
DISCUSSION
The E2 ubiquitin conjugases UBE2T and UBE2W can
act in the ubiquitination of FANCI/D2. However, UBE2T
is only the conjugase required for activation of the FA
pathway in response to MMC/ICL, and biallelic loss-of-
function mutations of UBE2T lead to the FA phenotype of
chromosome instability (36–39,92–94). Our experiments to
model recombination at the UBE2T locus were prompted
by an FA patient with inactivating duplication and deletion
mutations in UBE2T and whose fibroblasts were hypersen-
sitive to the genotoxins DEB and cisplatin, and defective
in monoubiquitination of FANCD2 in response to MMC
(40). Surprisingly, theUBE2T duplication was almost com-
pletely absent in genomic DNA from the patient’s periph-
eral blood, consistent with normal thrombocyte, leukocyte
and platelet counts as well as normal bone marrow cellular-
ity.
To test whether homology dependent recombination at
the UBE2T AluYa5 elements could account for the genetic
reversion in this patient, we integrated single copy model
UBE2T alleles into HeLa/406 cells using FLP recombinase
(45–50). ThemodelUBE2T alleles contained red (dTomato)
and green (eGFP) reporter genes separated by an I-Sce1
cleavage site so that the recombination events after DNA
double strand breakage could be monitored on protein lev-
els by flow cytometry.
I-Sce1 expression in the reporter cell lines DF2 and DF3
resulted in the cleavage of greater than 75% of the model
UBE2T alleles and changes in color that were monitored
by fluorescence microscopy and flow cytometry. The loss of
the dTomato or eGFPORFs and the sizes of themajor PCR
products from the I-Sce1 treated cells were consistent with
homology-dependent Alu-mediated recombination. From
these results, we conclude that an endogenous DSB likely
initiated recombinational reversion of the duplicatedmater-
nal UBE2T allele in the proband and possibly partial dele-
tion of one UBE2T allele in the father.
The structures of the recombined reporter loci indicated
that HDR had occurred primarily between pairs of Alu el-
ements. However, analysis of flow sorted clonal cell pop-
ulations indicated that more complex mechanisms leading
to unexpected patterns of loss of both color reporter genes
were also active in a minority (<15%) of cells. Knockdown
or inhibition of proteins involved in DNA damage signal-
ing and HR (RAD51, ATM, CtIP), but not NHEJ (DNA-
PKcs), inhibited recombination between Alu elements, sup-
porting the view that classical single strand annealing was
responsible for Alu-mediated recombination. In DF2 cells,
inhibition shifted approximately half of the recombina-
tions from HDR (RFP+, eGFP–) to NHEJ to yield RFP+
eGFP+ cells that generated I-Sce1 resistant PCR products.
Single strand annealing is a RAD51-independent mech-
anism of recombination (42,80,81,95). To test for the role
of RAD51 in I-Sce1 repair in the model UBE2T locus,
we used the RAD51 inhibitors B02, RI-1 and RI-2, which
have been used extensively to analyze RAD51-mediated
recombination (72–75,96–115). Each of these drugs re-
duced Alu-mediated HDR by ∼50%; however, these drugs
may have off-target effects in addition to inhibition of
RAD51. Therefore, we also tested the DNA repair in con-
junction with BRCA2 knockdown, which has been shown
to block RAD51-dependent HR, and increase error-prone
forms of recombination (81). Our results are consistent with
these previous observations, in that BRCA2 knockdown in-
creased the percentage of RFP–, GFP+ and RFP–, eGFP–
cells, which result from aberrant recombination (Figure 3).
However, BRCA2 knockdown did not affect the percentage
of RFP+ eGFP– cells, the majority of which appear to have
resulted from SSA (Figure 5). Although not all functions of
RAD51 (e.g. S-phase focus formation (116) and replication
fork reversal (117)) are dependent on BRCA2 (118), we con-
clude that RAD51-independent homology directed SSA is
responsible for at least a large proportion of Alu-mediated
recombination in our system.
We also observed that Alu 1/IVS1 acts in cis to promote
Alu 2/3 homology directed recombination to yield red cells.
In DF2 cells, Alu 1 is 2 kb upstream of Alu 2, which is
well within the length of DNA that is resected in advance
of homology directed repair (119,120). In flow cytometry-
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sorted cells (Figure 3), only one of nine double negative
clones showed the expected Alu 1/3 recombination prod-
uct. This result suggests that there are sequences in the con-
struct that allow homeologous recombinations that retain
(lanes 3, 6) or delete (lanes 1, 2, 4, 5, 7, 8) the PCR primer
sites. One possible explanation for the positive influence of
Alu 1/IVS1 on HR is that the Alu 1 sequence or its binding
proteins (121–123) on the sister chromatid aid in position-
ing the Alu 2/IVS6 to anneal to the Alu3/IVS6 sequence
during intrachromosomal SSA, akin to the phenomenon of
transvection (124–127).
Since HR had been implicated in the reversion of the du-
plication in theUBE2T−/− patient’s hematopoietic cells, we
tested for this activity following UBE2T knockout in DF3
and U2OS cells. An approximate 50% decrease in RFP–
eGFP+ cells in UBE2T knockout DF3 cells implied that
redundant homology-dependent repair pathways are oper-
able for Alu-mediated recombination. InUBE2T−/− U2OS
cells, the DR-GFP assay showed a reproducible decrease
of ∼40% in HR, suggesting that UBE2T plays a role in
HR in addition to activation of FANCI/D2 for ICL re-
moval, but that one or more UBE2T-independent parallel
pathways also exist for residual HR inUBE2T−/− cells. An
overview of the decrease in homologous recombination de-
tected by the DR-GFP assay due to insufficiency of several
FA orHR-related proteins (Supplementary Table S1) shows
a wide range of effects, with knockdown of several known
FA proteins showing incomplete inhibition of HR, as in the
case of UBE2T knockout.
We propose that UBE2T-dependent homology directed
recombination is one mechanism of Alu-mediated rever-
sion of the model UBE2T locus and that in UBE2T null
patient cells, a UBE2T-independent residual mechanism of
HR such as SSA was responsible for contraction of the par-
tially duplicated UBE2T locus. We conclude that a sponta-
neous DSB in the duplicated UBE2T locus of the FANCT
patient that had occurred in an hematopoietic stem cell
was sufficient for UBE2T independent, Alu-mediated re-
combination that restored a wild-type UBE2T gene and
thereby provided survival advantage for that stem cell and
its progeny.
Finally, we note that the dual fluorescence flow cytomet-
ric assay for recombination in DF cells is quantitatively re-
sponsive to DNA double strand breaks and the manipula-
tion of DNA repair pathways, indicating that this is a ro-
bust gateway system that could be adapted to the analysis
of Alu-mediated homologous recombination in the human
BRCA1 locus in breast tumors (6) and other diseases in-
cluding FA (9,128), or more generally to probe the causes
and consequences of DSBs in human cells (129). Combined
with knockdowns of specific genes of interest or testing of
chemical/medicinal compounds, the dual fluorescence sys-
tem can quantitatively report on the contribution of specific
proteins to HR and NHEJ and is therefore well suited for
high throughput systematic studies of Alu-mediated recom-
bination events.
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